Latest Advances

  • Journal: Transplantation and cellular therapy
  • Published —
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
  • Journal: Transplantation and cellular therapy
  • Published —
Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
  • Condition: Cold Agglutinin Disease
  • Journal: Frontiers in immunology
  • Treatment Used: Daratumumab
  • Number of Patients: NULL
  • Published —
The study researched the effects of daratumumab in patients with cold agglutinin disease.
  • Condition: Patients with Multiple Myeloma (MM) in Kenya
  • Journal: JCO global oncology
  • Treatment Used: Thalidomide and Dexamethasone; Bortezomib, Thalidomide, and Dexamethasone; and Melphalan and Prednisolone Chemotherapy Regimens
  • Number of Patients: 221
  • Published —
This study determined the survival outcomes of patients with multiple myeloma (MM) in Kenya.
  • Condition: Relapsed or Refractory Acute Lymphocyte Leukemia (ALL), Lymphoma, or Multiple Myeloma (MM)
  • Journal: Frontiers in immunology
  • Treatment Used: Chimeric Antigen Receptor (CAR) T Cell Treatment
  • Number of Patients: 142
  • Published —
This study evaluated the use of chimeric antigen receptor (CAR) T cell therapies in patients with relapsed or refractory acute lymphocyte leukemia (ALL), lymphoma, or multiple myeloma (MM).
  • Condition: Relapsed Refractory Multiple Myeloma (RRMM)
  • Journal: JCO global oncology
  • Treatment Used: Generic Pomalidomide
  • Number of Patients: 0
  • Published —
This study evaluated the outcomes of pomalidomide in patients with relapsed and refractory multiple myeloma (bone cancer; RRMM).
  • Condition: Cancer
  • Journal: Oncoimmunology
  • Treatment Used: Anti-PD-1/PD-L1 Combinations vs. Standard of Care (SOC)
  • Number of Patients: 0
  • Published —
This review of the literature compared the effectiveness and safety of anti-PD-1/PD-L1 combinations versus standard of care in the treatment of patients with cancer.
  • Condition: Multiple Myeloma
  • Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
  • Treatment Used: Haploidentical Hematopoietic Stem Cell Transplantation and Cyclophosphamide
  • Number of Patients: 1
  • Published —
The study researched the use of haploidentical hematopoietic stem cell transplantation and cyclophosphamide for treating multiple myeloma.
  • Condition: Plasma Cell Disease
  • Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Treatment Used: Plerixafor combined with G-CSF
  • Number of Patients: 49
  • Published —
The objective of this study was to analyze the effect and safety of plerixafor combined with G-CSF mobilization in plasma cell disease.
  • Condition: Relapsed and Refractory Multiple Myeloma
  • Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Treatment Used: Daratumumab
  • Number of Patients: 46
  • Published —
The aim of this study was to investigate the effectiveness and safety of daratumumab for the treatment of relapsed and refractory multiple myeloma (RRMM).
  • Condition: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
  • Journal: Journal of Korean medical science
  • Treatment Used: Total Body Irradiation (TBI)
  • Number of Patients: 0
  • Published —
This article summarized the use of total body irradiation (TBI) in the conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT).
  • Condition: B-cell Malignancies, Mantle cell lymphoma, and Multiple Myeloma
  • Journal: Frontiers in immunology
  • Treatment Used: CAR T-Cell Therapy
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T-cell therapy in the treatment of patients with B-cell malignancies, mantle cell lymphoma, and multiple myeloma.
Showing 1-12 of 380